title: Novel therapy for asthma.
abstract: The health burden of asthma is increasing globally at an alarming rate, providing a strong impetus for the development of new therapeutics. Currently available inhaled bronchodilators and anti-inflammatory drugs are effective in most asthmatics, but this palliative therapy requires long-term daily administration. Despite considerable efforts by the pharmaceutical industry, it has been difficult to develop novel therapeutic agents; the leukotriene antagonists and synthesis inhibitors being the only new class of asthma treatments to have been licensed in the last 30 years. It is clearly important to understand more about the underlying mechanisms of asthma and about how current drugs work before rational improvements in therapy can be expected. There are numerous therapies in clinical development that combat the inflammation found in asthma, specifically targeting eosinophils, IgE, adhesion molecules, cytokines and chemokines, inflammatory mediators and cell signalling. In particular, there is the obvious need for new therapy for severe asthma that is poorly controlled by high doses of corticosteroids, as well as agents to counter acute emergency asthma. A long-term goal is to develop disease-modifying immunotherapy, that could be introduced in childhood to alter the natural history of asthma. Thanks to the extensive efforts of the pharmaceutical industry, in the near future we can expect the introduction of a range of novel therapies for asthma.
authors.affiliation: National Heart and Lung Institute, Royal Brompton Clinical Studies Unit, Imperial College, London, UK.
authors.forename: S A
authors.initials: SA
authors.lastname: Bryan
authors.forename: M J
authors.initials: MJ
authors.lastname: Leckie
authors.forename: T T
authors.initials: TT
authors.lastname: Hansel
authors.forename: P J
authors.initials: PJ
authors.lastname: Barnes
mesh_terms: D000276:Adjuvants, Immunologic; D000319:Adrenergic beta-Antagonists; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents; D000998:Antiviral Agents; D001249:Asthma / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D001993:Bronchodilator Agents; D018925:Chemokines / Q000037:antagonists & inhibitors; D016207:Cytokines / Q000037:antagonists & inhibitors; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D015316:Genetic Therapy; D005938:Glucocorticoids; D006801:Humans; D007166:Immunosuppressive Agents; D007167:Immunotherapy; D020024:Leukotriene Antagonists; D008517:Phytotherapy; D011994:Recombinant Proteins
chemical_list: D000276:Adjuvants, Immunologic; D000319:Adrenergic beta-Antagonists; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D000998:Antiviral Agents; D001993:Bronchodilator Agents; D018925:Chemokines; D016207:Cytokines; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; D005938:Glucocorticoids; D007166:Immunosuppressive Agents; D020024:Leukotriene Antagonists; D011994:Recombinant Proteins